Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 16INDUSTRY 12NIH 10NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Lymphoid 9Myeloid 4Other neoplasm 2Sarcoma 1Plasma cell 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 42Docetaxel 33Paclitaxel 31Tamoxifen 29Doxorubicin 29Trastuzumab 25Radiotherapy 21Epirubicin 16Letrozole 15Anastrozole 12exemestane 11Fluorouracil 11Capecitabine 10Bevacizumab 10palbociclib 9Immunohistochemistry 9Fulvestrant 9Filgrastim 9Lapatinib 8Zoledronic Acid 7Methotrexate 7Magnetic Resonance Spectroscopy 7Gene Expression Profiling 7pertuzumab 6Triptorelin Pamoate 6Taxes 6Surgical Procedures, Operative 6Microarray Analysis 6Goserelin 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × fludarabine × Breast × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡